flavoxate
Regulatory sources consulted
Approved indications
- Symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency, and incontinence associated with urologic disorders.
Contraindications
Absolute
- Gastrointestinal obstruction or ileus, gastrointestinal bleeding, achalasia, urinary retention, glaucoma, myasthenia gravis, or hypersensitivity.
Clinical warnings
- Major warning · Use cautiously in renal impairment because the active metabolite is mainly cleared by the kidney. It may cause drowsiness or visual disturbance. — CIMA/AEMPS, ficha técnica 53032
Adverse events
Common (≥1%)
Nausea · Drowsiness · Visual disturbance · Vomiting, dry mouth, or dyspepsia
Rare but serious
Anaphylaxis or anaphylactic shock · Urinary retention · Jaundice or liver disorder
Pregnancy and lactation
Preferably avoid during pregnancy. Do not use while breastfeeding.
Recent literature (PubMed)
Chromones, characterized by a benzo-annulated γ-pyrone core, represent a privileged scaffold, offering a diverse pharmacological spectrum. Clinically approved drugs such as disodium cromoglycate and flavoxate underscore their therapeutic significance. Recent advancements in synthetic strategies have facilitated the development of novel chromone derivatives with improved bioactivity, selectively modulating key molecular targets implicated in cancer, inflammation, diabetes, infectious diseases, and neurodegenerative disorders. Furthermore, their emerging utility as imaging probes and regulators of pharmacologically relevant targets, such as pyridoxal phosphatase (PDXP), highlights their expanding role in modern drug discovery. This review provides a comprehensive overview of recent progress in the identification of bioactive chromone-based natural products and synthetic analogs, emphasizing their therapeutic potential. Additionally, critical innovations in recent synthetic methodologies and targeted therapeutic applications are discussed, reinforcing chromones as a sustainable and multifunctional framework for next-generation drug development.